
    
      Patients who complete the Part 2 Week 28 visit in study KNS-760704-CL201 and patients with
      ALS who are actively receiving RTPB
      [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydro-chloride monohydrate]
      under Research IND #60,948 may be eligible to participate in this study.

      Eligible patients will receive 1 tablet of KNS-760704 150 mg every 12 hours (Q12H) (300 mg
      total daily dose) for up to 180 weeks.
    
  